Figure 5

BC-PDE FET responses correlate with clinical outcomes. (A) ROC curve used to determine the threshold for resistance/sensitivity to FET treatment using combined fold change tumour apoptosis and necrosis in BC-PDEs. The area under the curve is 0.721 ± 0.105 with an optimal cut off of 2.33 giving 67.5% sensitivity and 83.3% specificity. (B) Kaplan–Meier progression free survival for all cases correlated with sensitivity of BC-PDEs to FET with regard to apoptosis and necrosis. (C) ROC curve used to determine the threshold for resistance/sensitivity to FET treatment using percent change in FET-treated tumour Ki67 levels relative to vehicle control in BC-PDEs. The area under the curve is 0.721 ± 0.12, with an optimal cut off of 0.933 giving 66.7% sensitivity and 85% specificity. (D) Kaplan–Meier progression free survival for all cases correlated with sensitivity of BC-PDEs to FET with regard to change in tumour Ki67. (E) ROC curve used to determine the threshold for resistance/sensitivity to FET treatment using percent change in FET-treated stroma Ki67 levels relative to vehicle control in BC-PDEs. The area under the curve is 0.692 ± 0.117, with an optimal cut off of 0.0032 giving 66.7% sensitivity and 82.5% specificity. (F) Kaplan–Meier progression free survival for all cases correlated with sensitivity of BC-PDEs to FET with regard to change in stroma Ki67. Statistics for Kaplan–Meier were Mantel-Cox log-rank test, p < 0.05 was considered significant.